A Phase 1 trial shows a personalized DNA vaccine (GNOS-PV01) is safe and doubles survival rates for aggressive glioblastoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results